JAK2V617F/STAT5 signaling pathway promotes cell proliferation through activation of Pituitary Tumor Transforming Gene 1 expression

Biochemical and Biophysical Research Communications

Volumn 398, Issue 4, 2010, Pages 707-712

  Shen, Xu Liang ^a,b   Wei, Wu ^a   Xu, Hong Liang ^a   Zhang, Mei Xiang ^a   Qin, Xiao Qi ^a   Shi, Wen Zhi ^a   Jiang, Zhi Ping ^a   Chen, Yi Jian ^c   Chen, Fang Ping ^b  

^a CHANGZHI MEDICAL COLLEGE   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c GANNAN MEDICAL UNIVERSITY   (China)

Author keywords

AG490; HEL cell; JAK2V617F; Myeloproliferative neoplasms; Proliferation; PTTG1

Indexed keywords

JANUS KINASE 2; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PHENYLALANINE; SECURIN; STAT5 PROTEIN; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG POTENCY; ERYTHROCYTOSIS; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

CELL LINE; CELL PROLIFERATION; HUMANS; JANUS KINASE 2; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TYRPHOSTINS;

EID: 77955429088     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.07.005     Document Type: Article

References (37)

1. Wadleigh M., Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int. J. Hematol. 2010, 91:174-179.
2. James C., Ugo V., Le Couedic J.P., et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature 2005, 434:1144-1148.
3. Kralovics R., Passamonti F., Buser A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 2005, 352:779-790.
4. Levine R.L., Wadleigh M., Cools J., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7:387-397.
5. Baxter E.J., Scott L.M., Campbell P.J., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365:1054-1061.
6. Steensma D.P. JAK2V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. J. Mol. Diagn. 2006, 8:397-411. (quiz 526).
7. Larsen T.S., Pallisgaard N., Møller M.B., Hasselbalch H.C. The JAK2V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype. Eur. J. Haematol. 2007, 79:508-515.
8. Carobbio A., Finazzi G., Antonioli E., et al. JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera. Exp. Hematol. 2009, 37:1016-1021.
9. Larsen T.S., Pallisgaard N., Møller M.B., Hasselbalch H.C. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden. Hematology 2008, 13:71-76.
10. Xing S., Wanting T.H., Zhao W., et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood 2008, 15(111):5109-5117.
11. Akada H., Yan D., Zou H., et al. Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 2010, 115:3589-3597.
12. Kakar S.S. Assignment of the human tumor transforming gene TUTR1 to chromosome band 5q35.1 by fluorescence in situ hybridization. Cytogenet. Cell Genet. 1998, 83:93-95.
13. Salehi F., Kovacs K., Scheithauer B.W. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr. Relat. Cancer 2008, 15:721-743.
14. Domínguez A., Ramos-Morales F., Romero F., et al. A. hPTTG, a human homologue of rat PTTG, is overexpressed in hematopoietic neoplasms: evidence for a transcriptional activation function of hPTTG. Oncogene 1998, 17:2187-2193.
15. Wang Z., Yu R., Melmed S. Mice lacking pituitary tumor transforming gene show testicular and splenic hypoplasia, thymic hyperplasia, thrombocytopenia, aberrant cell cycle progression, and premature centromere division. Mol. Endocr. 2001, 15:1870-1879.
16. Rubinek T., Chesnokova V., Wolf I., Wawrowsky K., Vlotides G., Melmed S. Discordant proliferation and differentiation in pituitary tumor-transforming gene-null bone marrow stem cells. Am. J. Physiol. Cell Physiol. 2007, 293:C1082-C1092.
17. Wernig G., Mercher T., Okabe R., Levine R.L., Lee B.H., Gilliland D.G. Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood 2006, 107:4274-4281.
18. Meydan N., Grunberger T., Dadi H., et al. Inhibition of acute lymphoblastic leukaemia by a JAK-2 inhibitor. Nature 1996, 379:645-648.
19. Li R., Yang N., Zhang L., et al. Inhibition of JAK/STAT signaling ameliorates mice experimental nephrotic syndrome. Am. J. Nephrol. 2007, 27:580-589.
20. Martin P., Papayannopoulou T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982, 216:1233-1235.
21. Tabilio A., Rosa J.P., Testa U., et al. Expression of platelet membrane glycoproteins and alpha-granule proteins by a human erythroleukemia cell line (HEL). EMBO J. 1984, 3:453-459.
22. Walz C., Crowley B.J., Hudon H.E., et al. Activated JAK2 with the V617F point mutation promotes G1/S phase transition. J. Biol. Chem. 2006, 281:18177-18183.
23. Quentmeier H., MacLeod R.A., Zaborski M., Drexler H.G. JAK2V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006, 20:471-476.
24. Saharinen P., Takaluoma K., Silvennoinen O. Regulation of the JAK2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 2000, 20:3387-3395.
25. Zhao R., Xing S., Li Z., et al. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 2005, 280:22788-22792.
26. Socolovsky M., Fallon A.E., Wang S., Brugnara C., Lodish H.F. Fetal anemia and apoptosis of red cell progenitors in STAT5A-/-5b-/- mice: a direct role for STAT5 in Bcl-X(L) induction. Cell 1999, 98:181-191.
27. Hitoshi Y., Lin N., Payan D.G., Markovtsov V. The current status and the future of JAK2 inhibitors for the treatment of myeloproliferative diseases. Int. J. Hematol. 2010, 91:189-200.
28. Ito T., Shimada Y., Kan T., et al. Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma. Cancer Res. 2008, 68:3214-3224.
29. Vlotides G., Eigler T., Melmed S. Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr. Rev. 2007, 28:165-186.
30. Bradshaw C., Kakar S.S. Pituitary tumor transforming gene: an important gene in normal cellular functions and tumorigenesis. Histol. Histopathol. 2007, 22:219-226.
31. Espina A.G., Méndez-Vidal C., Moreno-Mateos M.A., et al. Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. Mol. Biol. Cell 2009, 20(14):3353-3362.
32. Kim D., Pemberton H., Stratford A.L., et al. Pituitary tumour transforming gene (PTTG) induces genetic instability in thyroid cells. Oncogene 2005, 24:4861-4866.
33. Salehi F., Kovacs K., Scheithauer B.W., et al. Immunohistochemical expression of pituitary tumor transforming gene (PTTG) in pituitary adenomas: a correlative study of tumor subtypes. Int. J. Surg. Pathol. 2010, 18:5-13.
34. Watkins R.J., Read M.L., Smith V.E., et al. Pituitary tumor transforming gene binding factor: a new gene in breast cancer. Cancer Res. 2010, 70:3739-3749.
35. Kakar S.S., Jennes L. Molecular cloning and characterization of the tumor transforming gene (TUTR1): a novel gene in human tumorigenesis. Cytogenet. Cell Genet. 1999, 84:211-216.
36. Hamid T., Malik M.T., Kakar S.S. Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol. Cancer 2005, 4:3.
37. Bernal J.A., Luna R., Espina A., et al. Human securin interacts with p53 and modulates p53-mediated transcriptional activity and apoptosis. Nat. Genet. 2002, 32:306-311.